Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease
characterised by fibrosis of the lung parenchyma and loss of lung function. Although the …

Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the
extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with …

Angiogenesis is a critical process required for tumor progression. Newly formed blood
vessels provide nutrition and oxygen to the tumor contributing to its growth and …

Nintedanib, a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis, has anti-fibrotic, anti-inflammatory, and anti-angiogenic activity. We explored the …

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary
fibrosis treatment by regulatory agencies and available for clinical use worldwide. These …

Inflammation and angiogenesis are two hallmarks of carcinoma. The proinflammatory
cytokine interleukin-17 (IL-17) facilitates angiogenesis in lung cancer; however, the …

In European countries, nearly 10% of all hospital admissions are related to respiratory
diseases, mainly chronic life-threatening diseases such as COPD, pulmonary hypertension …

Vascular endothelial growth factor receptor (VEGFR) is a very important receptor tyrosine
kinase (RTK) that can induce angiogenesis, increase cell growth and metastasis, reduce …

Retinochoroidal vascular diseases are the leading causes of blindness in the developed
world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of …